DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with Inherited Genetic Risk

Recruiting

Conditions: Pancreatic Cancer

First Posted Date: 2015-06-23

Last Posted Date: 2025-01-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 200

Registration Number: NCT02478892

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

FDG-PET/CT Imaging as Early Predictor of DP

Completed

Conditions: Lymphoma

Interventions: Other: There is no intervention

First Posted Date: 2015-06-19

Last Posted Date: 2023-07-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 9

Registration Number: NCT02476734

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Dietary Flaxseed in NSCLC

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Dietary Supplement: Flaxseed

First Posted Date: 2015-06-18

Last Posted Date: 2021-06-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 33

Registration Number: NCT02475330

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases

Conditions: Pancreatic Diseases

First Posted Date: 2015-06-15

Last Posted Date: 2025-04-04

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 100

Registration Number: NCT02471170

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity

Withdrawn

Conditions: Severe or Mild Toxicity From Radiotherapy and/or Chemotherapy

First Posted Date: 2015-06-11

Last Posted Date: 2019-09-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT02469194

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Autologous OC-L Vaccine and Ovarian Cancer

Phase 1

Terminated

Conditions: Primary Peritoneal Cancer
Primary Ovarian Cancer
Fallopian Tube Cancer

Interventions: Other: Montanide
Other: poly-ICLC (Hiltonol),
Biological: OC-L

First Posted Date: 2015-05-25

Last Posted Date: 2020-04-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 3

Registration Number: NCT02452775

Locations: 🇺🇸
Ovarian Cancer Research Center, Philadelphia, Pennsylvania, United States

Evaluating Therapeutic Response to Novo-TTF

Not Applicable

Completed

Conditions: Glioblastoma Multiforme

Interventions: Device: Novo-TTF

First Posted Date: 2015-05-12

Last Posted Date: 2024-07-19

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT02441322

Locations: 🇺🇸
University Of Pennsylvania, Philadelphia, Pennsylvania, United States

A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Drug: pembrolizumab

First Posted Date: 2015-05-05

Last Posted Date: 2022-06-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 33

Registration Number: NCT02434354

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

First Posted Date: 2015-03-05

Last Posted Date: 2020-04-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 100

Registration Number: NCT02380196

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)

Phase 1

Completed

Conditions: Uterine Cervix Cancer

Interventions: Drug: Nelfinavir
Biological: Cisplatin

First Posted Date: 2015-02-16

Last Posted Date: 2020-04-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 6

Registration Number: NCT02363829

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy